Literature DB >> 31279015

Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project.

Amit Garg1, Erica Neuren2, Denny Cha2, Joslyn S Kirby3, John R Ingram4, Gregor B E Jemec5, Solveig Esmann5, Linnea Thorlacius5, Bente Villumsen6, Véronique Del Marmol7, Aude Nassif8, Maia Delage8, Thrasyvoulos Tzellos9, Dagfinn Moseng9, Øystein Grimstad9, Haley Naik10, Robert Micheletti11, Sandra Guilbault12, Angie Parks Miller13, Iltefat Hamzavi14, Hessel van der Zee15, Errol Prens15, Naomi Kappe15, Christine Ardon15, Brian Kirby16, Rosalind Hughes16, Christos C Zouboulis17, Georgios Nikolakis17, Falk G Bechara18, Lukasz Matusiak19, Jacek Szepietowski19, Amelia Glowaczewska19, Saxon D Smith20, Noah Goldfarb21, Steven Daveluy22, Christina Avgoustou23, Evangelos Giamarellos-Bourboulis23, Steven Cohen24, Yssra Soliman24, Elena Gonzalez Brant25, Oleg Akilov25, Christopher Sayed26, Jerry Tan27, Afsaneh Alavi28, Michelle A Lowes29, José Carlos Pascual30, Hassan Riad31, Shani Fisher32, Arnon Cohen33, So Yeon Paek34, Barry Resnik35, Qiang Ju36, Lanqi Wang36, Andrew Strunk2.   

Abstract

BACKGROUND: A needs assessment for patients with hidradenitis suppurativa (HS) will support advancements in multidisciplinary care, treatment, research, advocacy, and philanthropy.
OBJECTIVE: To evaluate unmet needs from the perspective of HS patients.
METHODS: Prospective multinational survey of patients between October 2017 and July 2018.
RESULTS: Before receiving a formal HS diagnosis, 63.7% (n = 827) of patients visited a physician ≥5 times. Mean delay in diagnosis was 10.2 ± 8.9 years. Patients experienced flare daily, weekly, or monthly in 23.0%, 29.8%, and 31.1%, respectively. Most (61.4% [n = 798]) rated recent HS-related pain as moderate or higher, and 4.5% described recent pain to be the worst possible. Access to dermatology was rated as difficult by 37.0% (n = 481). Patients reported visiting the emergency department and hospital ≥5 times for symptoms in 18.3% and 12.5%, respectively. An extreme impact on life was reported by 43.3% (n = 563), and 14.5% were disabled due to disease. Patients reported a high frequency of comorbidities, most commonly mood disorders. Patients were dissatisfied with medical or procedural treatments in 45.9% and 34.6%, respectively. LIMITATIONS: Data were self-reported. Patients with more severe disease may have been selected.
CONCLUSION: HS patients have identified several critical unmet needs that will require stakeholder collaboration to meaningfully address.
Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Global VOICE; acne inversa; care; comorbid conditions; diagnosis; hidradenitis suppurativa; life impact; pain; patient; symptoms; treatment; unmet needs

Year:  2019        PMID: 31279015     DOI: 10.1016/j.jaad.2019.06.1301

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  24 in total

1.  Comprehensive approach to managing hidradenitis suppurativa patients.

Authors:  Erin K Collier; Jennifer L Hsiao; Vivian Y Shi; Haley B Naik
Journal:  Int J Dermatol       Date:  2020-04-06       Impact factor: 2.736

2.  Management Landscape of Pediatric Hidradenitis Suppurativa.

Authors:  Justine R Seivright; Erin Collier; Tristan Grogan; Terri Shih; Marcia Hogeling; Vivian Y Shi; Jennifer L Hsiao
Journal:  Skin Appendage Disord       Date:  2021-09-22

3.  Treating hidradenitis suppurativa patients with adalimumab: a real-life experience of a tertiary care center in Lisboa, Portugal.

Authors:  José Miguel Neves; Nélia Cunha; André Lencastre; Joana Cabete
Journal:  An Bras Dermatol       Date:  2022-09-10       Impact factor: 2.113

Review 4.  Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What's New?

Authors:  Soha Ghanian; Mika Yamanaka-Takaichi; Haley B Naik; Afsaneh Alavi
Journal:  Am J Clin Dermatol       Date:  2022-01-06       Impact factor: 6.233

5.  Hidradenitis Suppurativa Specialty Clinics in the USA.

Authors:  Justine R Seivright; Alyssa Thompson; Iltefat Hamzavi; Michelle A Lowes; Martina Porter; Vivian Y Shi; Jennifer L Hsiao
Journal:  Skin Appendage Disord       Date:  2021-05-28

6.  Diagnosis and management of hidradenitis suppurativa in women.

Authors:  Erin K Collier; Ram K Parvataneni; Michelle A Lowes; Haley B Naik; Martin Okun; Vivian Y Shi; Jennifer L Hsiao
Journal:  Am J Obstet Gynecol       Date:  2020-09-24       Impact factor: 8.661

7.  Risk of Hidradenitis Suppurativa Comorbidities Over Time: A Prospective Cohort Study of Danish Blood Donors.

Authors:  Rune Kjærsgaard Andersen; Isabella Charlotte Loft; Kristoffer Burgdorf; Christian Erikstrup; Ole B Pedersen; Gregor B E Jemec
Journal:  Acta Derm Venereol       Date:  2021-01-20       Impact factor: 3.875

8.  Effect of Hidradenitis Suppurativa Disease Duration on Psychiatric Comorbidity.

Authors:  Hannu Tiri; Tuomas Hallikainen; Iason Vroullis; Jari Jokelainen; Kaisa Tasanen; Laura Huilaja
Journal:  Acta Derm Venereol       Date:  2020-07-28       Impact factor: 3.875

Review 9.  Quality of Life in Hidradenitis Suppurativa: An Update.

Authors:  Pavel V Chernyshov; Andrew Y Finlay; Lucia Tomas-Aragones; Francoise Poot; Francesca Sampogna; Servando E Marron; Sergey V Zemskov; Damiano Abeni; Thrasyvoulos Tzellos; Jacek C Szepietowski; Christos C Zouboulis
Journal:  Int J Environ Res Public Health       Date:  2021-06-06       Impact factor: 3.390

Review 10.  Pain management in hidradenitis suppurativa and a proposed treatment algorithm.

Authors:  Kevin T Savage; Vinita Singh; Zarine S Patel; Christine A Yannuzzi; Anne Marie McKenzie-Brown; Michelle A Lowes; Lauren A V Orenstein
Journal:  J Am Acad Dermatol       Date:  2020-09-17       Impact factor: 15.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.